| 中國醫藥大學 |
2010-11 |
Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis
|
陳偉峻(Wei-Chun chen); 陳煒(Wei- Chen); 曾冠欽(Guan-Chin Teseng); 賴學洲(Hsueh-Chou Lai); 施純明(Chuen-Ming Shih); 夏德椿(Te-Chun Hsia) |
| 中國醫藥大學 |
2010-11 |
Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
|
陳偉峻(Wei-Chun chen);陳煒(Wei- Chen);曾冠欽(Guan-Chin Teseng);賴學洲(Hsueh-Chou Lai);施純明(Chuen-Ming Shih);夏德椿(Te-Chun Hsia) |
| 高雄醫學大學 |
2007 |
GEFITINIB AS FIRST LINE THERAPY FOR ADVANCED OR METASTATIC NSCLC PATIENTS IN SOUTHERN TAIWAN
|
洪仁宇;黃明賢 |
| 高雄醫學大學 |
2007 |
GEFITINIB AS FIRST LINE THERAPY FOR ADVANCED OR METASTATIC NSCLC PATIENTS IN SOUTHERN TAIWAN
|
洪仁宇;黃明賢 |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
| 臺大學術典藏 |
2020-05-25T07:35:18Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Wang X; Park K.; Yang J.C.-H; Srimuninnimit V; Ahn M.-J; Chia-Chi Lin; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T |
| 國立臺灣大學 |
2009 |
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma
|
楊志新; YANG, CHIH-HSIN |
| 臺大學術典藏 |
2020-05-26T09:27:19Z |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
|
Mok T.S; Wu Y.-L; Thongprasert S; Yang C.-H; Chu D.-T; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; CHIH-HSIN YANG; Chewaskulyong B; Jiang H; Duffield E.L; Watkins C.L; Armour A.A; Fukuoka M. |
| 臺大學術典藏 |
2018-09-10T18:05:30Z |
Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior?
|
Chang, C.-H. and Lee, C.-H. and Wang, J.-Y.; JANN-YUAN WANG; CHIA-HAO CHANG |
| 臺大學術典藏 |
2020-08-13T05:24:06Z |
Gefitinib or erlotinib for previously treated lung adenocarcinoma: Which is superior?
|
Chang C.-H.;Lee C.-H.;Jann-Yuan Wang; Chang C.-H.; Lee C.-H.; JANN-YUAN WANG |
| 臺大學術典藏 |
2018-09-10T18:01:48Z |
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: A cohort study in Taiwan
|
Chang, C.-H. and Lee, C.-H. and Ko, J.-C. and Chang, L.-Y. and Lee, M.-C. and Wang, J.-Y. and Yu, C.-J.; Chong-Jen Yu; JANN-YUAN WANG; CHIA-HAO CHANG; JEN-CHUNG KO; LIH-YU CHANG |
| 臺大學術典藏 |
2022-06-14T03:22:08Z |
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan
|
LIH-YU CHANG |
| 臺大學術典藏 |
2017 |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Yu C.-J.; Lee M.-C.; JANN-YUAN WANG; Chang L.-Y.; Ko J.-C.; Lee C.-H.; Chang C.-H. |
| 臺大學術典藏 |
2021-03-11T08:29:35Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T08:34:20Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.;Lee C.-H.;Jen-Chang Ko;Chang L.-Y.;Lee M.-C.;Wang J.-Y.;Yu C.-J.; CHIA-HAO CHANG; Chih-Hsin Lee; JEN-CHANG KO; LIH-YU CHANG; Ming-Chia Lee; Jann-Yuan Wang; Chong-Jen Yu |
| 臺大學術典藏 |
2021-10-04T07:15:43Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2021-03-11T07:58:30Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; Yu C.-J. |
| 臺大學術典藏 |
2022-06-27T07:00:09Z |
Gefitinib or erlotinib in previously treated non–small-cell lung cancer patients: a cohort study in Taiwan
|
Chang C.-H.; Lee C.-H.; Ko J.-C.; Chang L.-Y.; Lee M.-C.; Wang J.-Y.; CHONG-JEN YU |
| 臺大學術典藏 |
2020-04-10T12:16:13Z |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
|
YU-YUN SHAO; Lin C.C.; Yang C.H. |
| 臺大學術典藏 |
2020-05-25T07:35:28Z |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
|
Shao Y.Y; Chia-Chi Lin; Yang C.H. |
| 臺大學術典藏 |
2020-05-26T09:27:17Z |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
|
Shao Y.Y;Lin C.C;Chih-Hsin Yang; Shao Y.Y; Lin C.C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2018-09-10T18:02:31Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee, C.K. ; Davies, L. ; Wu, Y.-L. ; Mitsudomi, T. ; Inoue, A. ; Rosell, R. ; Zhou, C. ; Nakagawa, K. ; Thongprasert, S. ; Fukuoka, M. ; Lord, S. ; Marschner, I. ; Tu, Y.-K. ; Gralla, R.J. ; Gebski, V. ; Mok, T. ; Yang, J.C.-H.; YU-KANG TU |
| 臺大學術典藏 |
2020-05-26T09:26:41Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Chih-Hsin Yang;Mok T;Gebski V;Gralla R.J;Tu Y.-K;Marschner I;Lord S;Fukuoka M;Thongprasert S;Nakagawa K;Zhou C;Rosell R;Inoue A;Mitsudomi T;Wu Y.-L;Davies L;Lee C.K; Lee C.K; Davies L; Wu Y.-L; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu Y.-K; Gralla R.J; Gebski V; Mok T; CHIH-HSIN YANG |
| 臺大學術典藏 |
2022-05-10T08:10:07Z |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
|
Lee C.K.; Davies L.; Wu Y.-L.; Mitsudomi T.; Inoue A.; Rosell R.; Zhou C.; Nakagawa K.; Thongprasert S.; Fukuoka M.; Lord S.; Marschner I.; YU-KANG TU; Gralla R.J.; Gebski V.; Mok T.; Yang J.C.-H. |
| 臺大學術典藏 |
2020-05-26T09:26:34Z |
Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses
|
Soria J.-C.;Thress K.S;Haddad V;Rukazenkov Y;Shi X;Ponce S;Atagi S;Lu Y;Chih-Hsin Yang;Wang J;Ahn M.-J;Yang J.-J;Nakagawa K;Wu Y.-L;Kim S.-W;Mok T.S.K; Mok T.S.K; Kim S.-W; Wu Y.-L; Nakagawa K; Yang J.-J; Ahn M.-J; Wang J; CHIH-HSIN YANG; Lu Y; Atagi S; Ponce S; Shi X; Rukazenkov Y; Haddad V; Thress K.S; Soria J.-C. |
